Skip to main content
KBS_Icon_questionmark link-ico

Principles of Medical Affairs

Key information

Subject area:

Life Sciences & Medicine

Course type:

Continuing Professional Development (CPD)

Credit level:



5 days

Available course dates:

To be confirmed

Course overview

*Please note that applicants to this short course should go via King's Apply (click red 'Apply' button on the right of this page) and select the following programme*:

Pharmaceutical Medicine Non-Award (Part-time)

Module code 7MCS0002

This module provides the background to the core principles that underpin the medical affairs function in bio-pharmaceutical companies.

What does this course cover?

This module aims to give students:

  • Knowledge of the commercialisation and marketing of medicines
  • Knowledge of how medicines are regulated
  • Skills to design data gathering instruments to use in the development of medicines
  • Skills to optimise patient engagement in the issues that touch patients especially in the development of medicines
  • Skills to communicate medical information to stakeholders of bio-pharmaceutical companies and internal colleagues

What will I achieve?

By the end of this module students will be able to:

  1. Critically appraise different commercialisation and marketing strategies for medicines
  2. Design a regulatory agency compliant medicine marketing strategy, including product advertising, funding bodies, and drug supply
  3. Critique the different roles and responsibilities within the pharmaceutical industry medical affairs function
  4. Debate the importance of engaging with patients for marketed medicines
  5. Create different strategies to communicate with and educate stakeholders regarding the company’s medicines

Who is this for?

Minimum entry requirements are either a medical degree (such as an MBBS) or a 2:1 first degree in pharmacy, pharmacology, biology, biochemistry, chemistry or related subject.



Course status:

Course closed

Full fee £2590

Home Students £1670

Overseas Students £2590

Express interest


Offered by